10 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 10 of 10 clinical reviews.
A head-to-head comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone on price, insurance coverage, pharmacy access, and regulatory status for longevity-focused patients.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity, covering mechanisms, trial data, dosing, safety, and when each agent fits best.
A clinical comparison of the side-effect profiles of nicotinamide mononucleotide/riboside (NMN/NR) and low-dose naltrexone (LDN), covering GI tolerance, sleep disruption, hepatic safety, and long-term risk data.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone for longevity, including when and how to switch between them safely.
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, covering pricing, prescribing access, insurance coverage, evidence base, and practical switching guidance.
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) side-effect profiles for longevity and immune-modulation use, with trial data, dosing context, and prescriber guidance.
A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) covering cost, access, insurance coverage, evidence quality, and practical prescribing considerations for longevity medicine.
A clinical comparison of the side-effect profiles of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including trial data, dosing considerations, and safety monitoring.
A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including when and how to switch between these interventions.
No head-to-head trial compares rapamycin and NMN in humans. Rapamycin shows 9-26% lifespan gains in mice; NMN lacks mammalian lifespan data.